title: Anticytokine therapy for periodontal diseases: Where are we now?
abstract: Periodontal destruction is initiated by bacteria that stimulate host responses leading to excess production of cytokines. Anticytokine therapy for periodontal diseases especially targets proinflammatory cytokines, that is, TNF-alpha, IL-1, and IL-6, because these are essential for the initiation of the inflammatory immune reaction and are produced for prolonged periods in periodontitis. This therapy aims to bind the cytokines with the receptors present on target cells such as the fibroblasts. The three basic treatment strategies are: (1) neutralization of cytokines, (2) blockage of cytokine receptors, and (3) activation of anti-inflammatory pathways, such as, immune-suppressive pathways.This new therapy can act as a host response modulator in the control of inflammatory diseases of gums and may provide the basis for new molecular therapeutic approaches to the treatment of periodontitis.
authors.affiliation: Post-graduate Student, Department of Periodontology, C.S.M.S.S Dental College and Hospital, Kanchanwadi, Aurangabad - 431 002, India.
authors.forename: Yogesh Prakash
authors.initials: YP
authors.lastname: Waykole
authors.forename: S S
authors.initials: SS
authors.lastname: Doiphode
authors.forename: P S
authors.initials: PS
authors.lastname: Rakhewar
authors.forename: Maya
authors.initials: M
authors.lastname: Mhaske
references.citation: J Clin Pharmacol. 2003 Apr;43(4):406-13
references.pmid: 12723461
references.citation: Arthritis Rheum. 2001 Feb;45(1):101-6
references.pmid: 11308054
references.citation: J Med Microbiol. 1998 Mar;47(3):187-8
references.pmid: 9511822
references.citation: J Clin Invest. 2001 Jul;108(1):73-81
references.pmid: 11435459
references.citation: N Engl J Med. 2001 Mar 22;344(12):907-16
references.pmid: 11259725
references.citation: J Periodontol. 1998 Dec;69(12):1419-25
references.pmid: 9926773
references.citation: Int J Immunopharmacol. 1995 Feb;17(2):141-5
references.pmid: 7544768
references.citation: J Periodontol. 2002 Apr;73(4):460-70
references.pmid: 11990448
references.citation: J Clin Periodontol. 2001 Mar;28(3):233-40
references.pmid: 11284536
references.citation: Infect Immun. 1999 Aug;67(8):4231-6
references.pmid: 10417196
references.citation: J Immunol. 1993 Dec 1;151(11):6602-7
references.pmid: 8245488
references.citation: J Immunol. 1997 Sep 1;159(5):2161-8
references.pmid: 9278303
references.citation: J Periodontol. 2000 Apr;71(4):573-8
references.pmid: 10807121
references.citation: J Pharmacol Exp Ther. 2007 Jan;320(1):56-63
references.pmid: 17041006
references.citation: J Immunol. 1998 Jan 1;160(1):403-9
references.pmid: 9551997
references.citation: FASEB J. 2006 Feb;20(2):401-3
references.pmid: 16373400
references.citation: J Immunol. 1996 Oct 15;157(8):3627-34
references.pmid: 8871663
references.citation: J Immunol. 2007 Nov 15;179(10):7021-9
references.pmid: 17982093
references.citation: J Immunol. 2005 Apr 1;174(7):4345-55
references.pmid: 15778399
references.citation: N Engl J Med. 2001 Oct 11;345(15):1098-104
references.pmid: 11596589
references.citation: Prog Med Chem. 2001;38:1-60
references.pmid: 11774793
references.citation: Endocr Rev. 1999 Jun;20(3):345-57
references.pmid: 10368775
references.citation: Nature. 2007 Jun 14;447(7146):869-74
references.pmid: 17568749
references.citation: J Clin Periodontol. 1986 May;13(5):418-30
references.pmid: 3522650